Hemophilia: A practical approach to genetic testing

Mayo Clinic Proceedings

Volumn 80, Issue 11, 2005, Pages 1485-1499

  Pruthi, Rajiv K ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE; DESMOPRESSIN;

BLEEDING DISORDER; DNA DETERMINATION; FOLLOW UP; GENE ISOLATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC POLYMORPHISM; GENETIC SCREENING; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LINKAGE ANALYSIS; QUALITY OF LIFE; REVIEW; VON WILLEBRAND DISEASE;

EID: 27644561782     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/80.11.1485     Document Type: Article

References (49)

1. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost. 1999;82:165-174.
2. Lorentz CP, Wieben ED, Tefferi A, Whiteman DAH, Dewald GW. Primer on medical genomics, part I: history of genetics and sequencing of the human genome. Mayo Clin Proc. 2002;77:773-782.
3. Ensenauer RE, Reinke SS, Ackerman MJ, Tester DJ, Whiteman DAH, Tefferi A. Primer on medical genomics, part VIII: essentials of medical genetics for the practicing physician. Mayo Clin Proc. 2003;78:846-857.
4. Soucie JM, Evatt B, Jackson D, Hemophilia Surveillance System Project Investigators. Occurrence of hemophilia in the United States. Am J Hematol. 1998;59:288-294.
5. Antonarakis SE, Kazazian HH Jr. The molecular basis of hemophilia A in man. Trends Genet. 1988;4:233-237.
6. White GC II, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, Factor VIII and Factor IX Subcommittee. Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85:560.
7. Mazurier C. von Willebrand disease masquerading as haemophilia A. Thromb Haemost. 1992;67:391-396.
8. Mazurier C, Meyer D. Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease-results of an international survey. Thromb Haemost. 1996;76:270-274.
9. Ingram GIC, Brozovic M, Slater NGP. Bleeding Disorders: Investigation and Management. 2nd ed. Oxford, England: Blackwell Scientific Publications; 1982:244-245.
10. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med. 1992;326:800-806.
11. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood. 1992;80:1998-2005.
12. Levine PH. Efficacy of self-therapy in hemophilia: a study of 72 patients with hemophilia A and B. N Engl J Med. 1974;291:1381-1384.
13. Mannucci PM, Mendolicchio L, Gringeri A. Use of prophylaxis to prevent complications of hemophilia. Adv Exp Med Biol. 2001;489:59-64.
14. Lee C. Recombinant clotting factors in the treatment of hemophilia. Thromb Haemost. 1999;82:516-524.
15. Aledort LM, Levine PH, Hilgartner M, et al. A study of liver biopsies and liver disease among hemophiliacs. Blood. 1985;66:367-372.
16. Soucie JM, Symons J IV, Evatt B, Brettler D, Huszti H, Linden J, Hemophilia Surveillance System Project Investigators. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia. 2001;7:198-206.
17. Soucie JM, NUSS R, Evatt B, et al, Hemophilia Surveillance System Project Investigators, Mortality among males with hemophilia: relations with source of medical care. Blood. 2000;96:437-442.
18. Rizza CR, Spooner RJ, Giangrande PL, UK Haemophilia Centre Doctors' Organization (UKCDO). Treatment of haemophilia in the United Kingdom 1981-1996. Haemophilia. 2001;7:349-359.
19. Tuddenham EG, McVey JH. The genetic basis of inhibitor development in haemophilia A. Haemophilia. 1998;4:543-545.
20. Thorland EC, Drost JB, Lusher JM, et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia. 1999;5:101-105.
21. Warder I, Ewenstein BM, Koerper MA, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol. 1997;19:23-27.
22. Warrier I, Lusher JM. Development of anaphylactic shock in haemophilia B patients with inhibitors. Blood Coagul Fibrinolysis. 1998;9(suppl 1):S125-S128.
23. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood. 1998;92:3983-3996.
24. Goodeve AC, Peake IR. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost. 2003;29:23-30.
25. Oldenburg J, Ananyeva NM, Saenko EL. Molecular basis of haemophilia A. Haemophilia. 2004;10(suppl 4):133-139.
26. Antonarakis SE, Rossiter JP, Young M, et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood. 1995;86:2206-2212.
27. Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet. 1993;5:236-241.
28. Bagnall RD, Waseem N, Green PM, Giannelli F. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood. 2002;99:168-174.
29. Gilles JG, Jacquemin MG, Saint-Remy JM. Factor VIII inhibitors. Thromb Haemost. 1997;78:641-646.
30. Chowdhury MR, Kabra M, Menon PS. Factor IX gene polymorphisms in Indian population. Am J Hematol. 2001;68:246-248.
31. Tefferi A, Wieben ED, Dewald GW, Whiteman DAH, Bernard ME, Spelsberg TC. Primer on medical genomics, part II: background principles and methods in molecular genetics. Mayo Clin Proc. 2002;77:785-808.
32. Liu Q, Nozari G, Sommer SS. Single-tube polymerase chain reaction for rapid diagnosis of the inversion hotspot of mutation in hemophilia A [letter]. Blood. 1998;92:1458-1459.
33. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science. 1985;230:1350-1354.
34. Buzin CH, Wen CY, Nguyen VQ, et al. Scanning by DOVAM-S detects all unique sequence changes in blinded analyses: evidence that the scanning conditions are generic. Biotechniques. 2000;28:746-750, 752-753.
35. Liu Q, Feng J, Buzin C, et al. Detection of virtually all mutations-SSCP (DOVAM-S): a rapid method for mutation scanning with virtually 100% sensitivity. Biotechniques. 1999;26:932, 936-938, 940-942.
36. Higuchi M, Kazazian HH Jr, Kasch L, et al. Molecular characterization of severe hemophilia A suggests that about half the mutations are not within the coding regions and splice junctions of the factor VIII gene. Proc Natl Acad Sci USA. 1991;88:7405-7409.
37. Naylor JA, Green PM, Montandon AJ, Rizza CR, Giannelli F. Detection of three novel mutations in two haemophilia A patients by rapid screening of whole essential region of factor VIII gene. Lancet. 1991;337:635-639.
38. Nichols WC, Seligsohn U, Zivelin A, et al. Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell. 1998;93:61-70.
39. Higuchi M, Antonarakis SE, Kasch L, et al. Molecular characterization of mild-to-moderate hemophilia A: detection of the mutation in 25 of 29 patients by denaturing gradient gel electrophoresis. Proc Natl Acad Sci U S A. 1991;88:8307-8311.
40. Kraus EM, Brettler DB. Assessment of reproductive risks and intentions by mothers of children with hemophilia. Am J Med Genet. 1988;31:259-267.
41. Ketterling RP, Bottema CD, Phillips JA III, Sommer SS. Evidence that descendants of three founders constitute about 25% of hemophilia B in the United States. Genomics. 1991;10:1093-1096.
42. Koeberl DD, Bottema CD, Sommer SS. Comparison of direct and indirect methods of carrier detection in an X-linked disease. Am J Med Genet. 1990;35:600-608.
43. Genetic counseling. Am J Hum Genet. 1975;27:240-242.
44. Biesecker BB. Goals of genetic counseling. Clin Genet. 2001;60:323-330.
45. Hook CC, DiMagno EP, Tefferi A. Primer on medical genomics, part XIII: ethical and regulatory issues. Mayo Clin Proc. 2004;79:645-650.
46. Gilchrist GS, Wilke JL, Muehlenbein LR, Danilenko-Dixon D. Intrauterine correction of factor VIII (FVIII) deficiency. Haemophilia. 2001;7:497-499.
47. Wertz DC, Fanos JH, Reilly PR. Genetic testing for children and adolescents: who decides? JAMA. 1994;272:875-881.
48. Kulkarni R, Lusher JM. Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature. J Pediatr Hematol Oncol. 1999;21:289-295.
49. Rodriguez V, Schmidt KA, Slaby JA, Pruthi RK. Intracranial haemorrhage as initial presentation of severe haemophilia B: case report and review of Mayo Clinic Comprehensive Hemophilia Center experience. Haemophilia. 2005;11:73-77.